Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628538 | 1.00 | BACE1 (0.40) | BACE1CTSD | |
| SCHEMBL8113997 | 0.85 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL2628583 | 0.84 | BACE1 (0.50) | BACE1CTSD | |
| SCHEMBL2633336 | 0.84 | BACE1 (0.50) | BACE1CTSD | |
| SCHEMBL10289124 | 0.78 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL2628530 | 0.78 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL8109278 | 0.77 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL2628531 | 0.77 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL2628536 | 0.74 | BACE1 (0.43) | BACE1CTSD | |
| SCHEMBL2628511 | 0.73 | BACE1 (0.42) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633315-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633315-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2167471-B1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130072483-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072483-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8173810-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-7803809-B2 | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009064418-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090036478-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036478-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2008147544-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147547-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | BACE1, APP, BACE2 | BACE1 1/4885CTSD 926/4885 |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | BACE1, BACE2, APP | BACE1 1/4885CTSD 615/4885 |
| US-20090036478-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | BACE1, BACE2, APP | BACE1 1/4885CTSD 851/4885 |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | BACE1 1/4885CTSD 368/4885 |
| US-20130072483-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | BACE1 1/4885CTSD 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.